Performance Summary - Virginie (02199.HK) reported revenue of HKD 3.84 billion for the six months ending September 30, 2025, a decrease of 3.45% year-on-year; net profit increased by 114.25% to HKD 145 million [1] - Huagang United (01001.HK) achieved revenue of HKD 1.023 billion, up 3.34% year-on-year; profit decreased by 3.64% to HKD 52.9 million [1] - Disen Creation (00113.HK) reported revenue of HKD 973 million, a year-on-year increase of 1.2%; net profit rose by 14.02% to HKD 150 million [1] - Sanhe Construction Group (03822.HK) generated revenue of HKD 470 million from customer contracts, a 20.8% increase year-on-year; net profit surged by 1364.7% to HKD 47.41 million [1] - Bojun Education (01758.HK) reported revenue of HKD 379 million for the year ending August 31, 2025, a decrease of 11.9%; losses increased by 227.6% to HKD 130 million [1] - Jiahua Holdings (00064.HK) reported revenue of HKD 172 million, down 21.01% year-on-year; profit increased by 57.59% to HKD 49.51 million [2] - Tiande Real Estate (00266.HK) reported revenue of HKD 152 million, a decrease of 2.5%; losses narrowed by 72.9% to HKD 75.43 million [3] - Kairun International Hotel (00105.HK) reported revenue of HKD 148 million, down 2.34%; losses decreased by 69.77% to HKD 148 million [4] - Safe Warehouse (00237.HK) reported revenue of HKD 84.1 million, down 9.97%; the company recorded a loss of HKD 17.56 million, shifting from profit to loss [4] Company News - Xinchen Power (01148.HK) established a strategic alliance with Sichuan Hongpeng Aerospace Equipment Intelligent Manufacturing in the field of aviation piston engines [5] - Qingdao Beer Co., Ltd. (00168.HK) plans to engage in wealth management investment activities with a maximum single-day balance of RMB 10 billion over the next 12 months [5] - Junshi Biosciences (01877.HK) plans to use up to RMB 2.4 billion of temporarily idle raised funds for cash management [5] - China Anshun Energy (02399.HK) signed a memorandum of understanding with Guo Heng for further investment and participation in energy-related projects [6] - Yanzhou Coal Mining (01171.HK) subsidiary plans to acquire 100% equity of a high-end support company for HKD 345 million [7] - Beijing Qingniao Huanyu (08095.HK) intends to invest approximately HKD 130 million to acquire the remaining 30% equity of Shanghai Shengjin Venture Capital Co., Ltd., focusing on new materials, energy conservation, and high-end equipment manufacturing [7] Financing and Buyback Activities - China Smart Technology (00464.HK) completed the issuance of a total of 11.7 million shares, raising approximately HKD 10.3 million [8] - Tencent Holdings (00700.HK) repurchased 1.036 million shares for HKD 636 million, with repurchase prices ranging from HKD 609 to HKD 620 [9] - China Petroleum & Chemical Corporation (00386.HK) repurchased 9.01 million shares for HKD 40.2765 million, with repurchase prices between HKD 4.42 and HKD 4.52 [10] - China Feihe (06186.HK) repurchased 4 million shares for HKD 16.6763 million, with repurchase prices ranging from HKD 4.12 to HKD 4.23 [10]

Core Viewpoint - Junshi Biosciences plans to utilize up to 2.4 billion yuan of temporarily idle raised funds for cash management to enhance fund efficiency and returns for the company and its shareholders [1] Group 1: Cash Management Purpose - The purpose of cash management is to improve the efficiency of raised funds and to reasonably utilize temporarily idle funds while ensuring that it does not affect the construction and use of investment projects [1] - The company aims to increase returns for both the company and its shareholders through this cash management strategy [1] Group 2: Investment Strategy - Junshi Biosciences will strictly control risks according to relevant regulations and intends to invest in high-safety, liquid principal-protected investment products [1] - The investment products include but are not limited to notice deposits, time deposits, agreement deposits, combination deposits, certificates of deposit, and structured deposits [1] - The funds will not be used for pledging or for investment purposes in securities [1]

Core Viewpoint - Junshi Biosciences (01877) plans to invest temporarily idle raised funds in low-risk, high-liquidity principal-protected investment products, adhering to relevant regulations [1] Group 1: Investment Strategy - The company intends to use a maximum of RMB 2.4 billion (including principal) of temporarily idle raised funds for cash management [1] - Investment products include but are not limited to notice deposits, time deposits, agreement deposits, combination deposits, certificates of deposit, and structured deposits [1] - The investment will not be used for pledging or for securities investment purposes [1] Group 2: Investment Duration and Management - The company plans to invest the idle funds in tranches with varying maturities, with the longest maturity not exceeding 12 months [1] - Within the specified limit and duration, the funds can be used in a rolling manner [1]

Core Viewpoint - The company plans to invest temporarily idle raised funds in low-risk, highly liquid principal-protected investment products, with a maximum investment of RMB 2.4 billion [1] Group 1: Investment Strategy - The company will strictly control risks according to relevant regulations [1] - The investment products include but are not limited to notice deposits, time deposits, agreement deposits, combination deposits, certificates of deposit, and structured deposits [1] - The funds will not be used for pledging or for investment purposes in securities [1] Group 2: Fund Management - The company plans to use a maximum of RMB 2.4 billion of temporarily idle raised funds for cash management [1] - The investment will be conducted in tranches based on the usage of raised funds and the company's operational conditions [1] - The maximum investment duration will not exceed 12 months, and funds can be rolled over within the specified limit and duration [1]

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1877） 海外監管公告 中國，上海，2025年11月27日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 国泰海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《國泰 海通證券股份有限公司關於上海君實生物醫藥科技股份有限公司使用暫時閒置募 集資金進行現金管理 ...

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於使用暫時閒置募集資金進行現金管理的公 告》，僅供參閱。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年11月27日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-068 上海君实生物医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二） 产品品种 公司将按照相关规定严格控制风险，拟使用暂时闲置募集资金投资安全性高、 流动性好的保本型投资产品（包括但不限于通知存款、定期存款、协定存款、组 合存款、存单及结构性存款等），且该等产品不得用于质押，不用于以证券投资 为目的的投资行为。 （三） 决议有效期 自公司董事会审议通过之日起 12 个月内有效。 （四） 投资额度及期限 公司计划使用最高不超过人民币 24 亿元（包含本数）的暂时闲置募集资金 进行现金管理。根据募集资金使用情况以及公司经营情况，将暂时闲置募集资金 分笔按不同期限投资上述产品，最长期限不超过 12 个月。在前述额度和期限内， 资金可以循环滚动使用。 （五） 资金来源 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 11 月 27 日召开第四届董事会第十五次会议，审议通过 ...

国泰海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上 海君实生物医药科技股份有限公司（以下简称"君实生物"、"公司"或"发行人"） 2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法 律法规和规范性文件的要求，就君实生物使用暂时闲置募集资金进行现金管理的 事项进行了审慎核查，并发表如下核查意见: 一、现金管理情况概述 （一）目的 为提高募集资金使用效率，合理利用部分暂时闲置募集资金，在确保不影响 募集资金投资项目建设和使用、募集资金安全且不变相改变募集资金用途的情况 下，增加公司资金收益，为公司及股东获取更多回报。 （二）产品品种 公司将按照相关规定严格控制风险，拟使用暂时闲置募集资金投资安全性高、 流动性好的保本型投资产品（包括但不限于通知存款、定期存款、协定存款、组 合存款、存单及结构性存款等），且该等产品不得 ...

Core Viewpoint - Junshi Biosciences (688180.SH) plans to utilize up to RMB 2.4 billion of temporarily idle raised funds for cash management [1] Group 1 - The company will invest the idle funds in different products based on the usage of raised funds and operational conditions [1] - The maximum investment period for these funds will not exceed 12 months [1] - The funds can be used in a rolling manner within the specified limit and timeframe [1]

Core Viewpoint - The company plans to utilize up to 2.4 billion yuan of temporarily idle raised funds for cash management, with a validity period of 12 months, allowing for rolling use of the funds [1] Group 1: Fund Management - The board of directors approved the use of idle funds from a specific A-share issuance in 2022, totaling 3.777 billion yuan raised, with a net amount of 3.745 billion yuan as of June 30, 2025 [1] - The company intends to invest in capital-preserving products, ensuring that the investment does not affect the implementation of fundraising projects [1] Group 2: Financial Strategy - The priority of the returns will be to replenish project funds and supplement working capital, with the funds to be returned to a designated account upon maturity [1]